In Vitro |
Sophoridine (0-500 μM; 48 hours) exhibits remarkable inhibition effects to the growth of human pancreatic, gastric, liver, colon, gallbladder, and prostate carcinoma cells with IC50 values of about 20 μM to 200 μM[1]. Sophoridine (0-20 μM; 48 hours) increases S phase cell population from 26.23% (control) to 38.67% in Miapaca-2 cells and from 29.56% (control) to 39.16% in PANC-1 cells, about a 1.5-fold and a 1.3-fold increase, respectively[1]. Sophoridine (0-20 μM; 48 hours) significantly increases bad and bax levels, and decreases bcl-2 and bcl-xl levels in contrast, with a significant increase in Bax/Bcl-2 ratio[1]. Cell Viability Assay[1] Cell Line: Normal cells: IOSE144, HL-7702 and LO2, BEAS-2B, GES-1, HEK 293 T, HPDE, FHC, Human cancer cells: PANC-1, Mapaca-1, hepG2, SGC-7901, CBC-SD,SGC-996,PC-3,MKN-45,MGC-803,Hela and HCT116 cells Concentration: 0, 3.9, 7.8, 15.5, 31, 62.5, 125, 250, 500 μM Incubation Time: 48 hours Result: Exhibited the most potent cytotoxicity to cancer cells. Cell Cycle Analysis[1] Cell Line: PANC-1 cells; Miapca-2 cells Concentration: 20 μM Incubation Time: 48 hours Result: Led to accumulated population in the S phase. Western Blot Analysis[1] Cell Line: PANC-1 cells; Miapca-2 cells Concentration: 20 μM Incubation Time: 48 hours Result: Induced the activation of intrinsic apoptosis pathway.
|